Human embryonic stem (hES) cells are renewable cell sources that have potential applications in regenerative medicine. The development of technologies to produce permanent and site-specific genome modifications is in demand to achieve future medical implementation of hES cells. We report herein that a baculoviral vector (BV) system carrying zinc-finger nucleases (ZFNs) can successfully modify the hES cell genome. BV-mediated transient expression of ZFNs specifically disrupted the CCR5 locus in transduced cells and the modified cells exhibited resistance to HIV-1 transduction. To convert the BV to a gene targeting vector, a DNA donor template and ZFNs were incorporated into the vector. These hybrid vectors yielded permanent site-specific gene addition in both immortalized human cell lines (10%) and hES cells (5%). Modified hES cells were both karyotypically normal and pluripotent. These results suggest that this baculoviral delivery system can be engineered for sitespecific genetic manipulation in hES cells.
INTRODUCTION
Permanent transgene expression in human embryonic stem (hES) cells could potentially be bene cial for basic biological studies and regenerative medicine. One possible application involves the expression of intracellular factors to provide additional stimulus to control the di erentiation of hES cells. Numerous studies on gene transfer to hES cells have been reported. 1, 2 Currently, the most e cient methodology to genetically engineer hES cells involves using a viral vector to introduce transgenes into the host genome. However, integrating vectors such as retroviral vectors pose the risk of insertional mutagenesis and oncogene activation. 3 e development of a targeting vector that is capable of integrating into predetermined genome sites can be a safer and more desirable approach. e insect baculovirus Autographa californica multiple nucleopolyhedrovirus has emerged as a promising gene delivery vector in recent years. is DNA virus is capable of entering mammalian cells and expressing transgenes under the control of mammalian promoters. [4] [5] [6] Transduction by baculovirus neither causes observable cytotoxicity at high multiplicity of infection (MOI), nor does it replicate inside mammalian cells, thereby reducing the safety risk. [5] [6] [7] [8] Another signi cant advantage of this double-stranded DNA virus as a vector is the large Autographa californica multiple nucleopolyhedrovirus genome (130 kb), which has been shown to accommodate transgenes of up to 38 kb. 9 Recently, baculoviral vectors (BVs) have been shown to be able to transduce human mesenchymal stem cells and hES cells. 10, 11 ese data revealed that BV is a promising and safe alternative gene therapy vehicle as compared to other pathogenic viral vectors.
Zinc-nger nucleases (ZFNs) have been shown to enhance the frequency of gene correction. [12] [13] [14] [15] [16] [17] [18] ZFNs are engineered DNAspeci c zinc-nger binding proteins fused to a nonspeci c DNA endonuclease domain (FokI). 14, 15, 18 Each zinc-nger domain recognizes three base pairs of DNA and a four-nger ZFN can then recognize a DNA sequence of 12 base pairs. e endonuclease domain of FokI must dimerize to cleave the double-stranded DNA sequence, thus ZFNs are designed in pairs that bind to the target sequence in the opposite orientation with the correct spacer. e double-strand break mediated by ZFNs is then repaired by either nonhomologous end joining, an error-prone repairing process, or homologous recombination (HR), an event that copies the homologous sequence from an adjacent DNA sequence. 19 ZFN-induced genetic modi cation has been applied to a variety of cell lines and several di erent species. [20] [21] [22] [23] [24] [25] Most notably, several groups have used ZFNs to enhance gene targeting e ciency in hES cells. 12, 13, 17 A recent report using integrase-defective lentiviral vectors (IDLVs) delivering ZFNs and a DNA donor template showed a high level of gene targeting events in hES cells. 17 Although the use of IDLVs greatly reduced the risk associated with the integrating event, some residual integration events remained. 26, 27 A follow-up study addressed this risk by using a virus-free system to perform 13 However, the gene editing e ciency was 20-fold lower than that of the IDLV system. To combine the strengths of both systems, we engineered a BV system to co-deliver both ZFNs and the DNA donor template to induce ZFN-mediated gene targeting. We report herein that the gene editing e ciency was comparable to that of the IDLVs system, and that no random integration events were observed in hES cells under our experimental conditions.
RESULTS

Construction of site-specific vectors
Site-speci c integration to a desirable site has been a long-standing goal in the eld of gene therapy. e CCR5 gene was chosen in this study as a site-speci c target to introduce a foreign gene because the homozygous null mutation is prevalent in a small population of individuals 28, 29 and disruption of this gene is well tolerated. 30 e C 2 H 2 ZFN protein was generated by fusing the CCR5-speci c zinc-nger proteins to engineered obligate heterodimers of the endonuclease domain of the FokI enzyme, which would minimize the nonspeci c cleavage. 31, 32 e Bac-ZFN construct consists of both the right and le ZFNs linked by a F2A sequence driven by the cytomegalovirus (CMV) internal promoter. ZFNs (ZFN-R: AAA CTG CAA AAG; ZFN-L: GAT GAG GAT GAC) (Figure 2a) can induce a double-strand break at the CCR5 locus.
en, with the delivery of a suitable DNA donor template, an HR event can occur and the donor sequence can be introduced into the CCR5 locus. e DNA donor template used in this study contains a green uorescent protein (GFP) expression cassette driven by the human elongation factor-1α promoter anked by CCR5 homology arms to initiate HR. e human elongation factor-1α promoter has been shown to e ciently drive the expression of the GFP reporter gene in hES cells. 11 Using the large transgene capacity of BV, we generated a Bac-ZFN-Donor construct by inserting the ZFN cassette directly into the Bac-Donor construct to facilitate both the double-strand break and transgene integration. We therefore constructed three di erent versions of BVs to deliver either ZFNs (Bac-ZFN), DNA donor template (Bac-Donor), or ZFNs and DNA donor template together (Bac-ZFN-Donor) (Figure 1) . Previously, IDLVs have been shown to successfully achieve gene modi cation in hES cells. 17 e gene editing process was achieved by co-delivery of both ZFNs and a DNA donor template to the target cells. To co-deliver both ZFNs, we constructed a lentiviral vector (FUW-ZFN) encoding two ZFNs linked by F2A and driven by the human ubiquitin-C promoter;
33 the woodchuck hepatitis virus posttranscriptional regulatory element was included downstream of the ZFNs to increase the level of transcription (Figure 1) .
ZFN-mediated target disruption by the BV
To determine whether CCR5 ZFNs could be e ciently delivered by a BV, we transduced the Ghost-CCR5 cell line, a human cell line that highly expresses autologous CCR5 genes, with the Bac-ZFN vector. e transduced cells were maintained in culture for 5 days. Flow cytometry analysis on the Bac-ZFN-transduced cells showed several populations with various levels of CCR5 expression, indicating the success of targeted gene disruption (Figure 2b) ) populations. In addition, we transduced both wild-type and ZFN-treated Ghost-CCR5 cells with either a lentiviral vector enveloped with a CCR5-tropsim HIV-1 glycoprotein (FUGW/GP160), or a control vector (FUGW/ vesicular stomatitis virus glycoprotein (VSVG)), to validate the disruption of the CCR5 gene. Consistent with previous data, a decrease in transduction e ciency was observed for the ZFNtreated cells exposed to FUGW/GP160 (Figure 2c; Supplementary  Figure S2 ). In the control experiment where ZFN-treated cells were transduced by FUGW/VSVG, transduction e ciency was unaltered, indicating that the decreased transduction was CCR5-dependent. To con rm the ZFN-induced cleavage at the target site, we performed a mismatch-sensitive Surveyor nuclease assay.
e DNA analysis of this assay revealed a disruption rate of 36% for the targeted gene in the ZFN-treated population, as compared to <1% gene disruption in the untreated Ghost-CCR5 cell line (Figure 2d) . We further sorted out the treated cells with low CCR5 expression (CCR5 low ). Flow cytometry analysis showed that these sorted cells contained ~70% CCR5-null cells. When these cells were subjected to the Surveyor assay, up to 60% of CCR5 alleles exhibited disruption (Figure 2d ). ese results demonstrate that ZFNs can be e ciently delivered by BV to induce double-strand breaks at the CCR5 target site and disable its expression. We made the attempt but failed to sort out pure CCR5-null cells by gating on the lowest corner of CCR5 low cells; ow cytometry analysis of cells cultured from these sorted cells always contained 20-30% CCR5-positive cells (data not shown).
ZFN-associated toxicity for vector-producing cells
Previously, Lombardo et al. reported the utilization of IDLVs to deliver ZFNs to disrupt the CCR5 gene. 17 However, their approach requires the target cells to be cotransduced by two vectors for a gene disruption. We hypothesized that incorporating both ZFNs linked by a 2A sequence in a single IDLV vector could improve the e ciency of gene targeting. To determine whether FUW-ZFN could mediate enhanced gene disruption, we generated a ZFNcontaining vector FUW-ZFN/VSVG and a ZFN-lacking vector FUW/VSVG. However, the lentiviral vector containing both ZFNs was not e ciently produced. A p24 assay revealed that the production level of FUW-ZFN/VSVG was <half of that of FUW/VSVG (Figure 3a) . Immunostaining to detect the protein 53BP1, which tends to localize at the DNA damage sites and form foci, revealed that the FUW-ZFN-transfected 293T cells yielded a higher amount of 53BP1-stained foci than the FUW-transfected cells, suggesting that the decreased production of FUW-ZFN/VSVG was due to the ZFN-mediated DNA cleavage (Figure 3b) . We further performed immunostaining on mammalian 293T and insect SF9 cells transduced with Bac-ZFN and found that 53BP1-stained foci were only observed in 293T cells. us, we suspect that the toxicity was due to both the presence of ZFNs that were only e ectively translated by the mammalian-active CMV promoter in 293T cells and the presence of the target sequence (CCR5) in the 293T genome (Figure 3c ). ese sets of results indicate that the reduction in virus production was due to ZFN-mediated toxicity associated with the lentiviral vector-producing cells (293T), whereas no such toxicity was detected in the BV producing cells (SF9).
ZFN-mediated targeted gene addition in cell lines
e transient nature of gene expression delivered by conventional BVs has limited the usage of this vector system in gene therapy. To extend the duration of BV-mediated gene expression, we constructed three BVs, Bac-ZFN, Bac-Donor, and Bac-Donor-ZFN, and tested their ability to achieve targeted integration into the CCR5 gene (Figure 4a) . We cotransduced both 293T and U87 cell lines with Bac-ZFN and Bac-Donor and observed that the GFP reporter gene could be stably expressed at 1 month post-transduction, whereas no detectable expression was seen when Bac-Donor was used alone (Figure 4b) . We then cotransduced the cell lines with Bac-ZFN and Bac-Donor at various MOI combinations to seek an optimal protocol for achieving higher e ciency of targeted gene integration. e ow cytometry analysis performed at 1 month post-transduction revealed that GFP expression culminated at a MOI of 150 for Bac-ZFN and a MOI of 500 for Bac-Donor, as evidenced by the high percentage (8-10%) of GFP expression (Figure 4c) . Transduction with Bac-Donor alone resulted in <1% GFP-positive cells, indicating the necessity of the ZFN-mediated double-strand break for e cient gene insertion. Similarly, when 293T and U87 cell lines were transduced by Bac-Donor-ZFN, the baculoviral construct that delivered both ZFNs and donor DNA to the cells, up to 6% targeted gene integration was observed (Figure 4d) .
In all of cell types tested, targeted integration into the CCR5 gene was con rmed by PCR analysis on GFP + cells sorted by uorescence-activated cell sorting at both integration junctions (Figure 4e) . To further characterize the double-strand breakmediated HR, we performed limiting dilution to isolate single clones. We employed a TaqMan quantitative PCR assay to determine the genome copies of the integrated GFP expressing cassette. is assay revealed that ~80% of the transduced cells do not contain randomly integrated viral vector (Supplementary Figure S1) . is series of experiments con rmed that BVs can mediate speci c gene addition to a predetermined target site with high e ciency.
ZFN-mediated targeted gene addition in hES cells
Stable gene expression is an important tool for future implementation of hES cells for regenerative medicine. To explore the feasibility of using ZFNs for targeted gene addition, we dissociated hES cells (H9) into single cells and incubated them with BVs (Bac-ZFN and Bac-Donor) at a MOI of 500 for 2 hours. We found that up to 4.38% of the hES cells were modi ed at 2 weeks post-transduction, whereas only a background level GFP was seen in hES cells modi ed with the Bac-Donor vector alone (Figure 5a ). e TaqMan quantitative PCR revealed that no random integration event was observed in the modi ed hES cells (Supplementary Figure S1d) . To con rm that the integration event was targeted to the desired CCR5 gene, we performed PCR ampli cations for the junctions of the integration sites and found that the GFP reporter cassette had undergone the predicted HR event at the CCR5 locus (Figure 5b) .
Transduction by BVs caused no microscopically observed cytotoxic e ects or morphological changes on the hES cells as compared to nontransduced control hES cells and the cells retained a normal karyotype (Figure 5c ). e transduced cells were immunostained to con rm the undi erentiated state of these modi ed hES cells. Transduced hES cells stably expressed the GFP reporter gene and remained undi erentiated, as indicated by the expression of the hES markers OCT4, NANOG, GCTM2, and SSEA4 (Figure 5d ). To con rm the pluripotency of the modi ed hES cells, transduced hES cells were sorted based on GFP expression, and these sorted hES cells were employed to form embryoid bodies (EBs). Reverse transcriptase-PCR analysis showed that the EBs were able to form all three germ layers, as the expression of germ layer-speci c markers were detected in EBs but absent in undifferentiated hES cells, indicating the pluripotency of the modi ed hES cells (Figure 5e) . Collectively, these data demonstrate that the ZFN-based BV approach allows for stable and e cient integration of transgenes in hES cells without any apparent detrimental e ects to the self-renewal and pluripotent state of the modi ed cells.
DISCUSSION
Baculoviruses have been shown to be a promising transient gene delivery vehicles in many mammalian cell types. 34 e high-level transduction, low cytotoxicity, lack of replication in mammalian cells, and large transgene capacity make the baculovirus a useful tool for delivering genes of interest. However, one major limitation in the broad range of applications of the BV system is the lack of permanent, site-speci c transgene expression. To address this challenge, others have generated a baculovirus/adeno-associated virus hybrid vector system containing a gene cassette anked by the inverted terminal repeats of adeno-associated virus to prolong the expression of the transgene. 11, 35 e limitation of this strategy is that the location of the integration site is restricted to the adenoassociated virus-preferred integration site and cannot be used to target-speci c genes. Permanent modi cation of the genome via site-speci c integration has been a long-standing goal in the eld, and has signi cant advantages over other viral integration approaches. Traditionally, the HR pathway has been exploited to edit a speci c locus. However, this approach is both labor-intensive and time-consuming as the e ciency of site-speci c HR is very low. To overcome the low HR e ciency, ZFNs have been used along with a donor template to enhance the gene targeting e ciency.
e double-strand break induced by ZFNs triggers two downstream repair mechanisms. One involves the nonhomologous end joining of the recessed strands at the double-strand break and results in localized deletion or insertion of nucleotides that leads to gene disruption. Another repair mechanism yields targeted gene addition via HR of the damaged DNA with either a sister chromatin or a homologous DNA donor template. By incorporating ZFNs and a DNA donor template, we investigated the feasibility of using BVs to achieve site-speci c integration of a DNA target sequence.
We demonstrated that permanent gene disruption can be achieved in established cells by BV delivery of ZFNs. We showed that by transducing CCR5-expressing cells with our engineered BV carrying ZFNs, we could generate cells composed of the CCR5 low , CCR5 med , and CCR5 high populations and obtain gene disruption with an overall e ciency of up to 36% by the Surveyor nuclease assay (Figure 2 ). An increased disruption of CCR5 alleles (60%) was seen a er sorting out the CCR5 low population containing ~70% CCR-null cells, suggesting a correlation between the disruption e ciency induced by Bac-ZFN and its target expression. We failed to sort out the pure CCR5-null population regardless of the stringency of gating criteria we applied on the ZFN-treated cells stained with the anti-CCR5 antibody. is suggests the limitation of the Ghost-CCR5 cell line and assays we chose for this investigation. e Ghost-CCR5 cells are mixed-cell populations generated by retrovirus-mediated gene delivery. 36 Although it is estimated for the Ghost-CCR5 cells to have an average of four CCR5 copies per cell, the copy number for individual cells varies. We could estimate that our average ZFN-disrupted CCR5 alleles were 1.44 copies per cell, but disruption for individual cells might di er greatly.
e mixed Ghost-CCR5 cells, combined with the heterogeneous ZFN-transduction and disruption, really complicated our analysis and limited our ability to conduct further quantitative data interpretation. We further demonstrated that targeted gene integration can be achieved by transducing cell lines with BV encoding ZFNs and a donor template (Figure 4) . To further expand the baculoviral delivering system to primary cell lines of therapeutic value, we transduced hES cells and showed that the modi cation eciency is comparable to that of IDLV-delivered ZFNs (5%) and ~20-fold higher than that of virus-free system (0.25%). 12, 17 e BV-transduced hES cells displayed neither karyotypic abnormalities nor any alteration to their pluripotency.
is study also highlighted the advantages of using BV as a gene delivery vehicle. First, the large cloning capacity of the vector allows us to generate a single construct to deliver both ZFNs and the donor template. e genome modi cation e ciency is comparable to that of the two-construct version (~7%) (Figure 4) . Second, since mammalian promoters, such as the CMV promoter used in this study, have been shown to be ine ective in driving the expression of transgenes in insect cells, the expression of ZFNs in these cells is highly restrained, resulting in greater viability of the producing cells. 37 In contrast, the CMV promoter has been shown to highly transcribe the transgene in vector-producing mammalian cells. e strong expression of both ZFNs in a single vectorproducing mammalian cell could lead to cytotoxicity, resulting in a decrease in vector production. Indeed, with a lentiviral vector carrying 2A-linked ZFNs, we observed a production issue associated with this type of ZFN-mediated cytotoxicity (Figure 3) .
In summary, we developed a novel BV that confers permanent gene disruption and genome modi cation in various mammalian cell lines as well as in hES cells by delivering ZFNs and a donor template. is system allows for safe and e cient genome modi cation of the target cell. Traditionally, genome is modied via integrating viral vectors such as retroviruses and lentiviruses, which tend to integrate into coding or regulatory regions of transcriptionally active genes, leading to possible gene silencing and insertional mutagenesis. 38, 39 Alternatively, transponsons such as Sleeping Beauty, PiggyBac, or phage integrase such as φ31 could also introduce permanent genome modi cations into target cells. [40] [41] [42] However, modi cations via these approaches may still impose position e ects, which could still lead to insertional mutagenesis. Our approach of using site-speci c HR via a ZFNmediated double-strand break allows us to pinpoint the exact site of integration, which is less likely to cause gene silencing and/or insertional mutagenesis. In principle, by engineering the ZFN binding domain and selecting the appropriate donor sequence, we could engineer BV-ZFN to direct the modi cation to any desirable genome site. Moreover, by selecting the target site, it will be possible to predict the level of transgene expression and exploit endogenous promoters to drive transgene expression, thus preventing gene silencing. Modi cation via HR can also be applied to treat diseased cells by replacing the defective genes with functional genes. e combination of ZFNs and the BV system can enable rapid generation of new cell lines and facilitate the study of the functions of speci c genes, which can advance novel developments in biotechnology and medicine.
MATERIALS AND METHODS
Maintenance and differentiation of the hES cells. e hES cell line H9 43 was maintained as described previously. 44 Brie y, hES colonies were maintained on mitotically inactivated mouse embryonic broblasts in media consisting of Dulbecco's modi ed Eagle's medium-F12 (Invitrogen, Carlsbad, CA) supplemented with 20% Knockout Serum Replacer (Invitrogen) and broblast growth factor-2 (4 ng/ml; Peprotech, Rocky Hill, NJ) plus antibiotics and -glutamine (1 mmol/l). Colonies were passaged weekly using mechanical dissection. To induce di erentiation, hES colonies were detached using 1 mg/ml of collagenase (Invitrogen). e hES cell clumps were transferred to suspension culture for 5 days to foster the formation of EBs. e EBs were then transferred to cell culture dishes coated with matrigel to promote attachment and outgrowth of di erentiated cells. Di erentiated cultures were collected for reverse transcriptase-PCR analysis 5 days following transfer.
Plasmid construction.
e plasmid pFasBac-Dual from Invitrogen was used as a shuttle vector to generate the recombinant BVs (pFB-ZFN, pFBDonor, and pFB-ZFN-Donor). e complementary DNAs (cDNAs) of the reported ZFNs targeting the human CCR5 17, 30 were synthesized by GeneArt (Regensburg, Germany). e ZFNs were cloned into the pcDNA3 vector (Invitrogen) via BamHI and EcoRI restriction sites. e resulting ZFN expression cassette including a CMV internal promoter and a BGH polyA tail was then cloned into pFastBac-Dual to yield pFB-ZFN. To generate the donor plasmid, the ZFN-targeted DNA was ampli ed with a primer pair (CCR5FW: TAC CGA GCT CGG ATC CTT AGA CCC TCT ATA ACA GTA ACT TCC TTT TAA AAA AGA CCT CTC CCA C; CCR5BW: TAG ATG CAT GCT CGA CTA GCG TCA ATA AAA ATG TTA AGA CTG AGT TGC AGC CG) and cloned into a TOPO plasmid (Invitrogen) via XhoI and BamHI restriction sites. A reporter expression cassette containing an human elongation factor-1α promoter, the GFP cDNA, and the polyA tail was then cloned into an EcoRV site that was inserted between the CCR5-ZFN-binding sites. To generate the pFB-Donor plasmid, the donor vector was PCR ampli ed with a pair of primers ( Vector production. Recombinant BVs with the described expression cassettes were produced and propagated in SF9 cells according to the manual of the Bac-to-Bac Baculovirus Expression system from Invitrogen. Budded viruses were ltered through a 0.45-µm pore size lter (Nalgene, Rochester, NY) to remove any cell debris, and concentrated via centrifugation at 10,000 r.p.m. for 5 hours and 20 °C. Viral pellets were resuspended in 1 ml of HBSS (Invitrogen). To determine the titers of the recombinant BVs, we adapted a qPCR assay to rst quantify the physical number of the viral particles. 45 e BacPAK Baculovirus Rapid Titer Kit (Clontech, Mountain View, CA) was then used to determine the infectious units. To generate the lentiviral vector FUW-ZFN, 293T cells were seeded in a 6 cm culture dish in Dulbecco's modi ed Eagle's medium supplemented with fetal bovine serum (Sigma, St Louis, MO, 10%), -glutamine (10 ml/l), penicillin, and streptomycin (100 units/ml) the night before transfection. 293T cells were transfected at a con uence of 80-90% with 5 µg of the lentiviral backbone vector (FUW-ZFN or FUW), and 2.5 µg each of pMDLg/pRRE, pRSV-Rev, and pVSVG via the standard calcium phosphate precipitation technique. 46 Cells were replenished with prewarmed media 4 hours post-transfection. Vectors were harvested 2 days post-transfection and ltered through a 0.45-µm pore size lter (Nalgene).
Surveyor nuclease assay. Genomic DNA was extracted from modied and control cells using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA). A 292-bp fragment of the CCR5 locus containing the ZFNs-binding site was ampli ed with the primer sets ZFNFW: AAG ATG GAT TAT CAA GTG TCA AGT CC and ZFNBW: CAA AGT CCC ACT GGG CG using Taq DNA polymerase (Fermentas, Glen Burnie, MD) and supplemented with 5 µCi α-P 32 dATP and 5 µCi α-P 32 dCTP. e PCR product was then puri ed with a G-50 column (GE Healthcare, Piscataway, NJ), denatured, reannealed and digested with Surveyor Nuclease (Transgenomic, Omaha, NE).
e resulting products were resolved on a nondenaturing 10% TBE polyacrylamide gel (Bio-Rad, Hercules, CA). e gel was dried and exposed and the resulting bands were quanti ed by phosphorimager (Bio-Rad). e proportion of ZFNdisrupted CCR5 alleles in the original sample is calculated using the formula: [1-SQRT (parental fraction)] × 100.
Viral transduction.
For viral transduction to the Ghost-CCR5 cell line, 0.05 million Ghost-CCR5 cells were seeded on a 24-well culture plate and spin-transduced with the BVs (Bac-ZFN, MOI = 500) or lentiviral vectors (FUW-ZFN/VSVG or FUW/VSVG) at 25 °C and 2,500 r.p.m. for 90 minutes using a RT Legend Centrifuge. A er replacing with fresh media, the treated cells were cultured for an additional 5 days at 37 °C and 5% CO 2 . To analyze the CCR5 disruption e ciency, the treated cells were stained by biotin-conjugated anti-CCR5 antibody (Invitrogen), followed by a secondary staining with phycoerythrin-conjugated streptavidin (BD Biosciences, San Jose, CA). Flow cytometry (BD FACSort; BD Biosciences) was then used to analyze the disruption e ciency.
For viral transduction to the 293T or U87 cell line, 0.5 million cells were seeded on a 24-well cell culture plate and spin-transduced with the indicated BVs (Bac-ZFN, Bac-Donor, or Bac-ZFN-Donor) at 25 °C and 2,500 r.p.m. for 90 minutes using a RT Legend Centrifuge. A er replacing with fresh media, the treated cells were cultured for additional 30 days at 37 °C and 5% CO 2 . Flow cytometry (BD FACSort) was then used to analyze gene addition e ciency.
For viral transduction to hES cells, single hES cells in suspension were used to avoid the e ect of virus absorption by the mouse embryonic broblast. On the day of the transduction, single cell suspensions were generated by treating hES colonies with 0.05% trypsin solution containing 0.2 g/l EDTA (Invitrogen) for 3 minutes. Detection of double-strand breaks in ZFN-treated cells. SF9 or 293T cells were transfected by Cellfectin (Invitrogen) using the protocol recommended by the manufacturer. Fluorescent images were acquired on a Yokogawa spinning-disk confocal scanner system (Solamere Technology Group, Salt Lake City, UT) using a Nikon eclipse Ti-E microscope equipped with a 60×/1.49 Apo TIRF oil objective and a Cascade II: 512 EMCCD camera (Photometrics, Tucson, AZ). An acousto-optical tunable lter controlled laser-merge system (Solamere Technology Group) was used to provide illumination power at each of the following laser lines: 491, 561, and 640 nm solid state lasers (50 mW for each laser). To image 53BP1, both treated and nontreated cells were seeded into a 35-mm glass-bottom culture dish and grown at 27 °C or 37 °C overnight. e seeded cells were rinsed with cold phosphate-bu ered saline and xed with 4% formaldehyde on ice for 10 minutes, and then immunostained with anti-53BP1 rabbit polyclonal antibodies (Bethyl Laboratories, Montgomery, TX) followed by incubation with Texas-Red anti-rabbit immunoglobulin G (Invitrogen). TO-PRO-3 iodide (Invitrogen) was also used for nuclear staining.
Targeted integration analysis. Genomic DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen). One hundred nanogram of genomic DNA was subjected to PCR using a primer pair of 5 CCR5FW (5 -CTT AGA ACA GTG ATT GGC ATC CAG TAT GTG CCC TC-3 ) and BGHPABW (5 -GCT GGG GAT GCG GTG GGC TCT ATG G-3 ) to con rm 5 targeted integration, and a primer pair of EF-1αFW (5 -GCC GAC CCC TCC CCC CAA CTT CTC-3 ) and 3 CCR5FW (5 -GGC TTA AAA GAT CTA ATC TAC TTT AAA CAG ATG CCA AAT AAA TGG ATG-3 ) to con rm 3 targeted integration. A primer pair of CCR5NTFW (5 -CTC TCC CTT CAC TCC GAA AGT TCC TTA TGT ATA TTT AAA AGA AAG C-3 ) and CCR5NTBW (5 -CTT GCA GTG AGG CTT CTG TCT TTG CCA GCA ATA G-3 ) was used to amplify nontargeted locus DNA. e PCR ampli ed products were resolved on 1% agarose gel and visualized by ethidium bromide staining.
Cell sorting and reverse transcription-PCR analysis. For sorting the GFP + cells, single cell suspensions were generated by treating hES colonies with 0.05% trypsin solution containing 0.2 g/l EDTA for 3 minutes. Dissociated cells were collected by centrifugation at 1,000 r.p.m. for 1 minute and resuspended in 2 ml of knockout Dulbecco's modi ed Eagle's medium containing 10 µmol/l of p160-Rho-associated coiled-coil kinase inhibitor. Cells were sorted with uorescence-activated cell sorting Aria SORP equipped with 100 µm nozzle (BD Biosciences).
Total RNA was extracted from hES cells or EBs using the RNeasy kit (Qiagen). First-strand cDNA was synthesized by the PowerScript Reverse Transcriptase system (BD Biosciences). Fi y nanogram of cDNA reaction mix was subjected to PCR ampli cation with the following primer pairs and the resulting products were electrophoresed on a 1% agarose gel. Immunohistochemistry and karyotypic analysis. For immunostaining hES cell colonies were washed with phosphate-bu ered saline and xed with 4% paraformaldehyde for 10 minutes. Cells were permeabilized with 0.1% Triton X-100 for 5 minutes at room temperature and then treated for
